An Overview of the Phase 3 Trial Assessing Lutetium Lu 177 Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 ASCO Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.

During the discussion, Strosberg gave an overview of the focus of the phase 3 trial assessing lutetium Lu 177 dotatate as a treatment for patients with midgut neuroendocrine tumors.